|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013227,
umls-concept:C0031437,
umls-concept:C0032105,
umls-concept:C0056476,
umls-concept:C0127400,
umls-concept:C0205410,
umls-concept:C0242485,
umls-concept:C0441889,
umls-concept:C0678133,
umls-concept:C1555029,
umls-concept:C2828389
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
1993-10-28
|
|
pubmed:abstractText |
Paclitaxel (Taxol) is the first of a new class of cytotoxic agents with activity against tumors resistant to other drugs. For clinical use, paclitaxel is currently formulated in a vehicle of 50% ethanol and 50% polyethoxylated surfactant Cremophor EL (Cremophor). We have previously shown that Cremophor will block the P-glycoprotein drug efflux pump responsible for the multidrug-resistant phenotype. Overexpression of P-glycoprotein is one mechanism of in vitro resistance to a number of currently used cytotoxic agents including paclitaxel.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1685-90
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8105099-Adult,
pubmed-meshheading:8105099-Aged,
pubmed-meshheading:8105099-Biological Assay,
pubmed-meshheading:8105099-Carrier Proteins,
pubmed-meshheading:8105099-Drug Resistance,
pubmed-meshheading:8105099-Female,
pubmed-meshheading:8105099-Flow Cytometry,
pubmed-meshheading:8105099-Glycerol,
pubmed-meshheading:8105099-Humans,
pubmed-meshheading:8105099-Membrane Glycoproteins,
pubmed-meshheading:8105099-Middle Aged,
pubmed-meshheading:8105099-Neoplasm Proteins,
pubmed-meshheading:8105099-Ovarian Neoplasms,
pubmed-meshheading:8105099-P-Glycoprotein,
pubmed-meshheading:8105099-Paclitaxel,
pubmed-meshheading:8105099-Pharmaceutical Vehicles,
pubmed-meshheading:8105099-Phenotype,
pubmed-meshheading:8105099-Tumor Cells, Cultured
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
|
|
pubmed:affiliation |
Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article
|
